Neurinnov Logo


The neurostimulation technology that resolves
unfulfilled demands in key medical conditions

Scroll down

Scroll Down

From paralysis
to movement

We are developing implantable neurostimulation solutions that enable patients living with complete tetraplegia to regain upper limb autonomy.

We are creating the first neurostimulation device that induces ‘selective’ activation of targeted muscles by steering electrical currents through one or a set of nerves.

Tomorrow, patients will be able to recover the functional use of one hand to perform everyday activities, such as grasping an object or even eating with a fork. In the future, our neurostimulation devices will be able to selectively activate any nerve target to potentially treat a variety of pathologies and deficiencies.

Early stage feasibility studies

The effectiveness of Neurinnov approach has been successfully tested on a preliminary clinical study with results published in Nature Scientific Reports Journal.

Key outcomes

Company Background

A spin-off from INRIA, the French national institute for research in digital science and technology, and the University of Montpelier, Neurinnov was founded in 2018 upon 20+ years’ research and expertise in micro-electronics, software engineering, electrophysiology and function physiology. Through its generic technology platform that adds value creation across many pathologies, Neurinnov is driving forward innovations aimed at addressing unmet needs in healthcare.


Neurinnov founders have vast expertise, culminating in decades of world-class research and development in micro-electronics, software engineering, electrophysiology and sensory-motor system, along with many years of experience leading successful medtech businesses. They have garnered several prestigious awards in research, including the “Grand prix” of the French National Academy of Sciences.

David Andreu, PhD

Co-founder, CTO and General Manager

David is a specialist in AIMD (Active Implantable Medical Device architecture, where he has won awards.

Learn more

David Guiraud, PhD

Co-founder, CSO and CEO

David is a specialist in electrophysiology and highly experienced in conducting clinical trials, including securing ethical committee approval for research.

Learn more

Latest NEWS

March 28, 2024

Neurinnov implied in AI-HAND European project

Neurinnov is very pleased to  announce its implication in the AI-Hand Project, launched on last November 28th.

This EU funded project under the programme HORIZON-EIC-2022-PATHFINDEROPEN-01 will last 42 months and intends to restore hand functions in low tetraplegia through selective neural electrical stimulation.

With our partners, we are collectively committed to the success of AI-HAND, in the hope of bringing a solution to patients.

Learn more about this projet.

March 28, 2024

Neurinnov implied in DREIMS European project

We are pleased to announced that Neurinnov contributes to the DREIMS european project under the program HORIZON EIC-2023-TRANSITION.

Il will last 36 months and intends to design and develop a multi-contact neural stimulator based on our selective neural stimulation technology in order to treat spinal cord injury, by combining biomaterials, pharmaceuticals, and electrical stimulation into an innovative therapeutic solution able to promote the closure of the spinal cord gap, with axonal regrowth and glial cell migration across large lesions in rodent and porcine models of spinal cord injury.

You can visit DREIMS' web site at:

January 31, 2023

Neurinnov wins Grand Prize Inn’Ovations award!

We are delighted to announce that we have been awarded a €30K prize in the ‘products or services for the future’ category at the Les Inn'Ovations awards by @AD'OCC, for our implantable neurostimulator, which enables patients with complete tetraplegia to regain upper limb autonomy.

Every year, Les Inn’Ovations award recognizes some of the most innovative projects in the Occitania region of France. The awarding jury was impressed by our active implantable medical device, powered by our remotely controlled ASIC chip, which helps restore the manual grip of patients who have suffered spinal cord injury allowing them to complete everyday tasks, such as eating with a fork or drinking through a straw, giving them greater independence.